Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting
13 déc. 2021 16h05 HE
|
Adaptive Biotechnologies
Analysis of the MASTER trial (Abstract 481) showed clonoSEQ’s ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patientsData in more than 30...
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
11 déc. 2021 17h30 HE
|
Neoleukin Therapeutics, Inc.
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma...
Proteona announces multiple ASH presentations highlighting novel gene signatures in hematological cancers identified using advanced single-cell biomarker discovery platform
08 déc. 2021 06h38 HE
|
Proteona
SINGAPORE, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Proteona, a single-cell precision medicine company, today announced that three abstracts from the company and its collaborators have been accepted for...
Aronora Announces Clinical Data to Be Presented at the 63rd American Society of Hematology Annual Meeting
06 déc. 2021 08h00 HE
|
Aronora, Inc
PORTLAND, Ore., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Aronora Inc., a clinical-stage biotechnology company developing innovative therapies for hematologic diseases, today announced that clinical data...
Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients
11 nov. 2021 17h52 HE
|
Adaptive Biotechnologies
Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain...
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
04 nov. 2021 09h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Plasma Fractionation Market Size ($40,731.98Mn by 2028) Lead by Immunoglobulin (6.3% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
02 nov. 2021 14h43 HE
|
The Insight Partners
New York, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Plasma Fractionation Market: Key InsightsAccording to our latest study on Plasma Fractionation Market Size, Share, Revenue, Forecast to 2028 - COVID-19...
Point-of-Care Molecular Diagnostics Market Size ($5,381.18Mn by 2028) Lead by Assays and Kits (13.4% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
29 oct. 2021 13h28 HE
|
The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Point-of-Care Molecular Diagnostics Market: Key InsightsAccording to our new research study on Point-of-Care Molecular Diagnostics Market Size and...
Plasma Fractionation Market Worth $41.4 Billion by 2027 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
21 oct. 2021 12h30 HE
|
Meticulous Market Research Pvt. Ltd.
Redding, California, Oct. 21, 2021 (GLOBE NEWSWIRE) -- According to a new market research report “Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous),...
Provectus Biopharmaceuticals Provides Update on Research into Oral Administration of PV-10® Immunotherapy for Treatments of Hematology, Oncology, and Virology
04 oct. 2021 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on the Company’s research into the systemic administration of Provectus’ investigational...